Last updated on August 2018

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Brief description of study

Hepatic impairment PK study

Detailed Study Description

This is a non randomized, open label, single dose, parallel cohort, multisite study to investigate the effect of varying degrees of hepatic impairment on the plasma pharmacokinetics (total and unbound) of PF-05221304 after a single oral dose administered in the fed state.

Clinical Study Identifier: NCT03309202

Contact Investigators or Research Sites near you

Start Over

Pfizer Call Center

Nemocnice Na Bulovce
Praha 8, Czechia

Pfizer Call Center

Pharmaceutical Research Associates CZ, s.r.o.
Praha 7, Czechia